Evaluation of Body Composition Improvement With Visceral Adiposity-Focused Anti-Obesity Telehealth Program
Recruiting
- Conditions
- Metabolic SyndromeCardiovascular DiseasesMetabolic DiseaseObesity
- Registration Number
- NCT05219240
- Lead Sponsor
- 20Lighter
- Brief Summary
A retrospective review of body composition changes in patients who participate in a 9-week non-invasive intensive health care provider supervised weight loss program as an overall cohort and in sub-cohorts of interest.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 2000
Inclusion Criteria
- Men and women 18 years of age and older, who enroll in the weight loss program are eligible for inclusion of the data review.
Exclusion Criteria
- Pregnancy or breastfeeding
- Current treatment of cancer
- Major organ transplant with immunosuppressant medication,
- Adult with a strict vegetarian diet,
- Certain psychiatric conditions (schizophrenia, bipolar disorder, manic depression)
- Adults with a BMI < 25.0 and no cardiovascular or metabolic comorbidities
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Body Mass Index (BMI) Change Baseline to 90 days Change in Body Mass Index (BMI)
Visceral Adiposity Change Baseline to 90 days Change in Visceral Adiposity
Body Fat % Change Baseline to 90 days Change in Body Fat %
Lean Body Mass Change Baseline to 90 days Change in Lean Body Mass
Intracellular Fluid % Change Baseline to 90 days Change in Intracellular Fluid %
Bodyweight Change Baseline to 90 days Change in bodyweight
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie visceral adiposity reduction in the 20Lighter Program for metabolic syndrome and obesity?
How does the 20Lighter telehealth program compare to standard-of-care interventions in improving body composition for patients with metabolic syndrome and cardiovascular diseases?
Are there specific biomarkers that predict successful outcomes in the 20Lighter Program for obesity-related metabolic diseases?
What are the known or potential adverse events associated with the 20Lighter Program and how are they managed in patients with metabolic syndrome?
What combination approaches or competitor drugs are being explored alongside telehealth programs for visceral adiposity reduction in obesity and metabolic disease?
Trial Locations
- Locations (1)
20Lighter Telehealth Program
🇺🇸Cheyenne, Wyoming, United States
20Lighter Telehealth Program🇺🇸Cheyenne, Wyoming, United StatesJessica Barnes, PhDContact